Newborn Mice Vaccination With BCG.HIVA²²² + MVA.HIVA Enhances HIV-1-specific Immune Responses: Influence of Age and Immunization Routes

Clin Dev Immunol. 2011;2011:516219. doi: 10.1155/2011/516219. Epub 2011 Apr 12.

Abstract

We have evaluated the influence of age and immunization routes for induction of HIV-1- and M. tuberculosis-specific immune responses after neonatal (7 days old) and adult (7 weeks old) BALB/c mice immunization with BCG.HIVA(222) prime and MVA.HIVA boost. The specific HIV-1 cellular immune responses were analyzed in spleen cells. The body weight of the newborn mice was weekly recorded. The frequencies of HIV-specific CD8(+) T cells producing IFN-γ were higher in adult mice vaccinated intradermally and lower in adult and newborn mice vaccinated subcutaneously. In all cases the IFN-γ production was significantly higher when mice were primed with BCG.HIVA(222) compared with BCGwt. When the HIV-specific CTL activity was assessed, the frequencies of specific killing were higher in newborn mice than in adults. The prime-boost vaccination regimen which includes BCG.HIVA(222) and MVA.HIVA was safe when inoculated to newborn mice. The administration of BCG.HIVA(222) to newborn mice is safe and immunogenic and increased the HIV-specific responses induced by MVA.HIVA vaccine. It might be a good model for infant HIV and Tuberculosis bivalent vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Adaptive Immunity / immunology*
  • Age Factors
  • Animals
  • Animals, Newborn
  • BCG Vaccine / genetics
  • BCG Vaccine / immunology*
  • CD8-Positive T-Lymphocytes / immunology
  • Drug Administration Routes
  • Epitopes / immunology
  • Female
  • HIV Infections / prevention & control*
  • HIV-1 / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Tuberculin / immunology
  • Vaccination*

Substances

  • AIDS Vaccines
  • BCG Vaccine
  • Epitopes
  • MVA-HIVA vaccine
  • Tuberculin